Overview: T2Candida Panel

Rapidly detect and identify Candida species—no blood culture required

Today, hospitals like Henry Ford in Michigan and Lee Health System in Florida, which have implemented the T2Candida® Panel, are reducing ICU and hospital lengths of stay, while minimizing the use of unnecessary antifungals, saving millions of dollars each year. T2Candida is the only FDA-cleared sepsis pathogen detection panel requiring no blood culture, delivering faster, easier and more accurate results in 3 to 5 hours from a simple blood draw.1

Run on the fully automated T2Dx Instrument, the T2Candida Panel identifies the five clinically relevant species of Candida directly from whole blood. This enables physicians to initiate appropriate therapy within hours of the blood draw. This is especially important given that research has shown that the mortality rate for sepsis rises 8% every hour treatment is delayed.2 Today, all other FDA-cleared Candida diagnostics rely on blood culture, which is hampered by a sensitivity of 50% and a lag time of up to 2 to 6 days for species identification or negative result.3 When up to half of infections are missed, even the most accurate blood-culture-reliant diagnostic cannot detect what blood culture missed.

The T2Candida Panel delivers:

  • 91.1% sensitivity1

  • 99.4% specificity1  

  • Limits of detection as low as 1 CFU/mL1

  • Species-specific results in an average of 3 to 5 hours directly from whole blood1

  • Accuracy even in the presence of antimicrobials

The T2Candida Panel detects the following species of Candida directly from whole blood: C. albicans, C. tropicalis, C. parapsilosis, C. krusei and C. glabrata.

A positive T2Candida Panel result enables clinicians to quickly treat patients with appropriate therapy, reducing costs, adverse outcomes, and patient mortality.4  

A negative T2Candida Panel result enables clinicians to avoid unnecessary antifungal therapy use, reducing antimicrobial costs, toxicity and resistance.


1. Mylonakis, E., Clancy, C. J., Ostrosky-Zeichner, L., Garey, K. W., Alangaden, G. J., Vazquez, J. A., … & Zervou, F. N. (2015). T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clinical Infectious Diseases, ciu959.
2. Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., … & Gurka, D. (2006). Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical care medicine, 34(6), 1589-1596.
3. Pappas, P. G., Kauffman, C. A., Andes, D. R., et. al. (2015). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical infectious diseases, civ933.
4. Bilir, S. P., Ferrufino, C. P., Pfaller, M. A., & Munakata, J. (2015). The economic impact of rapid Candida species identification by T2Candida among high-risk patients.